ArticleBMC infectious diseases2017
Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- New Insights Into the Therapeutic Management of Varicella Zoster Virus Meningitis: A Series of 123 Polymerase Chain Reaction-Confirmed Cases.Open forum infectious diseases · 2024Trial
- Impact of immunization strategies, public health and social measures on the incidence of varicella among children aged 0-14 years in Quzhou City.Human vaccines & immunotherapeutics · 2026Article
- Trends and patterns of varicella zoster virus infection in Kilifi: A population-based serosurvey.PLOS global public health · 2026Article
- Analysis and comparison of chickenpox outbreaks in two schools at different educational stages: a mixed retrospective observational study.BMC infectious diseases · 2025Observational
- Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.Journal of market access & health policy · 2025Article
- Analysis of sero-epidemiological characteristics of varicella in healthy children in Wuxi, China.Human vaccines & immunotherapeutics · 2024Article
- Analysis of antibody dynamics in Chinese children aged 1-3 years after single-dose varicella vaccination: A 42 months prospective study.Human vaccines & immunotherapeutics · 2024Article
- Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand.Human vaccines & immunotherapeutics · 2024Article
- Clinical description and outcome of overall varicella-zoster virus-related organ dysfunctions admitted in intensive care units: the VAZOREA cohort study.Annals of intensive care · 2024Article
- Seroprevalence rates in children aged 3-6 years after implementing a two-dose varicella vaccination: A observational study.Human vaccines & immunotherapeutics · 2023Observational
- Seroprevalence of Varicella Zoster Virus in the Eastern Province of Saudi Arabia in Post-vaccination Era.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2023Observational
- Herpesvirus-Associated Encephalitis: an Update.Current tropical medicine reports · 2022Review
- Amylin, Aβ42, and Amyloid in Varicella Zoster Virus Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells.The Journal of infectious diseases · 2021Article
- Uptrend prevalence of varicella parallel with low serum antibodies and low second-dose rate among children 10-14 years old in Wenzhou, China.Human vaccines & immunotherapeutics · 2021Article
- Research about the optimal strategies for prevention and control of varicella outbreak in a school in a central city of China: based on an SEIR dynamic model.Epidemiology and infection · 2020Article
- Effectiveness and failure rate of the varicella vaccine in an outbreak in Jiangsu, China: a 1:2 matched case-control study.Human vaccines & immunotherapeutics · 2020Article
- Seroprevalence and molecular characteristics of varicella-zoster virus infection in Chinese children.BMC infectious diseases · 2019Article
- Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.Human vaccines & immunotherapeutics · 2019Article
- Analysis of sero-epidemiological characteristics of varicella in healthy children in Jiangsu Province, China.BMC infectious diseases · 2018Article
- Preventing vertical virus infections: the role of serologic screening of pregnant women.Medical microbiology and immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent antibody to membrane antigen test (FAMA) as the gold standard.
methodsSerum samples of 13,433 children and adolescents aged 1-17 years included in the population-based German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003-2006) were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages (%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to determine the association between socio-demographic factors and VZV seropositivity.
resultsThe VZV seropositivity rate was 80.3% (95% CI: 79.3-81.3) in varicella-unvaccinated children and adolescents. VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-negative in by ELISA varied by age group: 2.6% in children aged 1-6 and 9% in children aged 7-17 years. Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43-0.99) and adolescents (OR: 0.62; 0.4-0.97).
conclusionIn the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren with a migration background and children without siblings have an increased risk of being VZV seronegative and should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.